Bacteroides uniformis as Next Generation Probiotics
Bacteroides uniformis (B. uniformis) has been reported to ameliorate the immunological dysfunctions and metabolic disorders, related to intestinal dysbiosis in obese mice. It is a candidate for next generation probiotics. At Creative Biolabs, we are highly experienced in live biotherapeutic product (LBP) development. We offer well-established and innovative One-Stop-Shop B. uniformis solutions for LBP development.
Introduction of B. uniformis
B. uniformis, originally isolated from human feces, is present in high abundance in the human gastrointestinal tract, and its abundance is often low in anaerobic infections. The clinical B. uniformis isolates were resistant to many cephalosporins-cephamycins as well as to penicillin G (all beta-lactam antibiotics). The cephalosporinase gene of B. uniformis (cblA) was characterised already in the early 90s. The abundance of the species B. uniformis is higher in breast-fed than in formula-fed infants. In particular, the strain B. uniformis CECT 7771 was originally isolated from stools of healthy breast-fed infants. B. uniformis CECT 7771 was the most studied strain and was previously considered a potential probiotic.
Fig.1 Comparative analysis of B. uniformis strains. (Benítez, 2017)
The Potential Role of B. uniformis for Disease Treatments
Studies have shown that the low abundance of B. uniformis in the intestines of formula-fed infants is associated with a high risk of obesity, suggesting that B. uniformis plays a potential role in alleviating obesity. This speculation was supported by the results of another study which demonstrated that the effects of B. uniformis CECT 7771 on obesity-related metabolic and immune alterations were promoted by feeding mice with a diet supplemented with B. uniformis CECT. Oral administration of B. uniformis CECT 7771 can alleviate the metabolic and immune dysfunctions associated with obesity in mice, such as body weight gain and liver steatosis; reduce liver cholesterol and triglyceride concentrations.
Fig.2 B. acidifaciens and B. uniformis regulate obesity-induced glucose intolerance in mice. (Wang, 2021)
Another potential probiotic function of B. uniformis is the reduction of acyl carrier protein expression, a fundamental component required for LPS biosynthesis in gram-negative bacteria and their growth and survival. LPS can promote the expression of pro-inflammatory cytokines and lead to chronic low-grade inflammation observed in obesity. Thus, B. uniformis could have a beneficial effect in alleviating inflammation.
What Services Can We Provide for B. uniformis at Creative Biolabs?
B. uniformis Related Products at Creative Biolabs
We supply a variety of B. uniformis strains of different preservation numbers as below. If you need other strains, please contact us.
Related Products
-
Customized strain fermentation supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
Creative Biolabs is 100% dedicated to the LBP industry. We have senior probiotics experts and a perfect technical platform. You can count on our skilled and passionate workforce to find the most suitable path for B. uniformis development research. If you are interested in our B. uniformis related services and products, please contact us for more information.
References
-
Benítez, et al. The glycolytic versatility of Bacteroides uniformis CECT 7771 and its genome response to oligo and polysaccharides. Frontiers in cellular and infection microbiology. 2017, 7: 383.
-
Wang, C.; et al. Roles of intestinal bacteroides in human health and diseases. Critical Reviews in Food Science and Nutrition. 2021, 61(21): 3518-3536.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
